SIG-007

SIG-007 is an investigational **cell therapy** from Sigilon Therapeutics for **Fabry disease**, a lysosomal storage disorder caused by deficiency of **alpha-galactosidase A**. The product consists of genetically modified cells engineered with a **non-viral vector** to express human alpha-galactosidase A and is designed to provide **continuous, prolonged enzyme delivery** using Sigilon's Shielded Living Therapeutics platform. Conceptually, it functions as an implanted enzyme-producing cell-based therapy intended to restore deficient Fabry enzyme activity and reduce downstream multi-organ disease manifestations such as renal, gastrointestinal, cerebrovascular, and cardiac complications.